Author: Alvotech

Posted Date:

March 30, 2026

Alvotech Files Annual Report with the SEC

Alvotech

March 30, 2026
Alvotech Q4 2025 and Full Year 2025 Financial Results

Alvotech

March 18, 2026
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Alvotech

March 4, 2026
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

Alvotech

February 8, 2026
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Alvotech

February 2, 2026
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg

Alvotech

January 29, 2026